What is #MapItForward & the Real World Genomics Study
Recent medical advances support the need for all cholangiocarcinoma patients to receive biomarker testing as part of their treatment, however the rate at which patients are actually receiving this testing in the real world is unknown. Real-world evidence is needed to capture the rates at which this crucial testing is being performed outside of the clinical trial setting.
This study will describe and characterize real-world patterns of biomarker testing in cholangiocarcinoma patients including the frequency, timing, and nature of testing performed. This is an important first step in understanding cholangiocarcinoma care patterns and advocating for better access to care and informing future drug development and you can help!